Alnylam Pharmaceuticals Revenue by Segment

Period Ending	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Amvuttra	859.20M	749.30M	651.30M	557.90M	451.20M	327.70M	195.60M	93.80M
Amvuttra Growth	90.43%	128.65%	232.98%	494.78%	1,690.48%	-	-	-
Collaboration	479.60M	849.70M	628.20M	546.20M	540.40M	142.20M	145.40M	134.80M
Collaboration Growth	-11.25%	497.54%	332.05%	305.19%	336.51%	24.08%	-11.88%	-25.48%
Onpattro	275.70M	307.00M	321.30M	354.60M	397.80M	461.20M	523.10M	557.60M
Onpattro Growth	-30.69%	-33.43%	-38.58%	-36.41%	-30.70%	-16.04%	2.63%	17.46%
Givlaari	250.50M	233.60M	229.40M	219.20M	207.00M	198.60M	185.90M	173.30M
Givlaari Growth	21.01%	17.62%	23.40%	26.49%	24.03%	29.80%	34.32%	35.60%
Oxlumo	156.10M	144.60M	128.20M	109.80M	100.90M	88.60M	79.30M	69.70M
Oxlumo Growth	54.71%	63.21%	61.66%	57.53%	54.99%	39.31%	22.00%	17.14%
Royalty	73.40M	59.90M	44.70M	40.60M	26.30M	19.10M	14.20M	8.10M
Royalty Growth	179.09%	213.61%	214.79%	401.23%	353.45%	430.56%	787.50%	575.00%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.